Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurorehabil Neural Repair ; 22(3): 262-78, 2008.
Article in English | MEDLINE | ID: mdl-18056009

ABSTRACT

OBJECTIVE: The myelin protein Nogo inhibits axon regeneration by binding to its receptor (NgR) on axons. Intrathecal delivery of an NgR antagonist (NEP1-40) promotes growth of injured corticospinal axons and recovery of motor function following a dorsal hemisection. The authors used a similar design to examine recovery and repair after a lesion that interrupts the rubrospinal tract (RST). METHODS: Rats received a lateral funiculotomy at C4 and NEP1-40 or vehicle was delivered to the cervical spinal cord for 4 weeks. Outcome measures included motor and sensory tests and immunohistochemistry. RESULTS: Gait analysis showed recovery in the NEP1-40-treated group compared to operated controls, and a test of forelimb usage also showed a beneficial effect. The density of labeled RST axons increased ipsilaterally in the NEP1-40 group in the lateral funiculus rostral to the lesion and contralaterally in both gray and white matter. Thus, rubrospinal axons exhibited diminished dieback and/or growth up to the lesion site. This was accompanied by greater density of 5HT and calcitonin gene-related peptide axons adjacent to and into the lesion/matrix site in the NEP1-40 group. CONCLUSIONS: NgR blockade after RST injury is associated with axonal growth and/or diminished dieback of severed RST axons up to but not into or beyond the lesion/matrix site, and growth of serotonergic and dorsal root axons adjacent to and into the lesion/matrix site. NgR blockade also supported partial recovery of function. The authors' results indicate that severed rubrospinal axons respond to NEP1-40 treatment but less robustly than corticospinal, raphe-spinal, or dorsal root axons.


Subject(s)
Growth Cones/drug effects , Myelin Proteins/antagonists & inhibitors , Myelin Proteins/pharmacology , Nerve Regeneration/drug effects , Peptide Fragments/pharmacology , Receptors, Cell Surface/antagonists & inhibitors , Spinal Cord Injuries/drug therapy , Animals , Behavior, Animal/drug effects , Denervation , Efferent Pathways/drug effects , Efferent Pathways/metabolism , Efferent Pathways/physiopathology , Female , GPI-Linked Proteins , Growth Cones/metabolism , Myelin Proteins/metabolism , Myelin Proteins/therapeutic use , Nerve Regeneration/physiology , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , Nogo Receptor 1 , Peptide Fragments/therapeutic use , Pyramidal Tracts/drug effects , Pyramidal Tracts/metabolism , Pyramidal Tracts/physiopathology , Raphe Nuclei/drug effects , Raphe Nuclei/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Cell Surface/metabolism , Recovery of Function/drug effects , Recovery of Function/physiology , Red Nucleus/drug effects , Red Nucleus/metabolism , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/physiopathology , Spinal Nerve Roots/drug effects , Spinal Nerve Roots/metabolism , Treatment Outcome , Wallerian Degeneration/drug therapy , Wallerian Degeneration/metabolism , Wallerian Degeneration/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...